Physician profile
Sharon Chu
NPI 1639304579
$3,725.31
in general payments reported to CMS, 2019-2025
15 companies · $914 in 2025
The $914 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $442 · 2021: $410 · 2022: $396 · 2023: $677 · 2024: $720 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,978.01 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $707.70 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $236.83 | 2019-2025 | Delstrigo, Pifeltro, Capvaxive |
| Novo Nordisk INC | $140.40 | 2023-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $138.69 | 2020-2023 | Bexsero, Pediarix |
| Theratechnologies INC. | $99.43 | 2020-2022 | |
| Abbvie INC. | $88.51 | 2022-2024 | Mavyret |
| Alkermes, INC. | $81.76 | 2022-2024 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $72.71 | 2024-2025 | Mounjaro, Zepbound |
| Organon LLC | $68.18 | 2025 | Nexplanon |
| Phadia US INC. | $35.05 | 2019-2020 | |
| Sanofi Pasteur INC. | $21.99 | 2023 | |
| Hologic Sales and Service, LLC | $21.85 | 2025 | Aptima |
| Allergan, INC. | $18.65 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.